Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 11Breast Carcinoma In Situ 2Weight Loss 1Paget's Disease, Mammary 1Neoplasms 1Fatigue 1Cognitive Dysfunction 1Carcinoma, Intraductal, Noninfiltrating 1Arthralgia 1

Interventions

Transcranial Direct Current Stimulation 4Walking 2lime 1Ultraviolet Therapy 1Tai Ji 1Sugars 1Standard of Care 1Sodium Chloride 1Silymarin 1Organization and Administration 1Methylphenidate 1Memantine 1Low-Level Light Therapy 1G(M1) Ganglioside 1Equine-Assisted Therapy 1Drug Therapy 1Donepezil 1Docosahexaenoic Acids 1Cognitive Training 1Cognitive Behavioral Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cognitive Dysfunction × Docosahexaenoic Acids × Breast × Clear all
NCT02517502 2022-01-24

Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy

University of Kansas Medical Center

Phase EARLY_PHASE1 Completed
24 enrolled
Breast

Breast Neoplasms, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡